Young Innovators of Medicines

younginnovatorsofmedicines.nl

The Young Innovators of Medicines form the youth branch of the Innovative Medicines Association. This is a trade association for 44 drug companies with a Dutch branch. The youth branch was founded in 2013, under the then name Jong Nefarma. The members of the Association have put forward 22 high potentials to participate in the youth department. In recent years, young people themselves have defined themes such as talent and development, partnership with other young (care) associations, connecting young people within the Association, and debate and advice on important topics in the pharmaceutical industry.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

PHARMACY MARKET

IQVIA AND NRX PHARMACEUTICALS COLLABORATE ON POTENTIAL MEDICAL SUPPORT FOR NOVEL COVID-19 TREATMENT

IQVIA™ | September 14, 2021

news image

IQVIA™ , a leading global provider of advanced analytics, technology solutions and clinical research services to the life sciences industry, today announced a transformative collaboration with NRx Pharmaceuticals (NRx). NRx is a company dedicated to creating innovative, life-saving treatments and bringing hope to those facing life-altering conditions with no approved disease-modifying therapies or cures. IQVIA is excited to collaborate with NRx as its designated partner, to provide pharmac...

Read More

BUSINESS INSIGHTS

ANOKION ANNOUNCES $35 MILLION EQUITY INVESTMENT FROM PFIZER

Anokion | October 19, 2022

news image

Anokion SA, a clinical-stage biotechnology company focused on treating autoimmune disease by restoring normal immune tolerance announced that Pfizer has made a $35 million equity investment in Anokion through the Pfizer Breakthrough Growth Initiative. In conjunction with the investment, Michael Vincent, M.D., Ph.D., senior vice president and chief scientific officer, Inflammation & Immunology, Pfizer, has joined the company’s scientific advisory board, which will be announced later thi...

Read More

MAJOR PHARMA COMPANIES INCLUDING NOVARTIS AND MERCK BUILD FEDERATED LEARNING PLATFORM FOR DRUG DISCOVERY

Venturebeat | September 17, 2020

news image

Last June, 10 major pharmaceutical companies — Amgen, Astellas, AstraZeneca, Bayer, Boehringer Ingelheim, GSK, Institut De Recherches Servier, Janssen, Merck, and Novartis — inked an agreement to build a shared platform called MELLODDY (Machine Learning Ledger Orchestration for Drug Discovery). In partnership with Nvidia, Owkin, and other tech partners, the group sought to leverage techniques like federated learning to collectively train AI on datasets without having to share any pro...

Read More

NEW JERSEY PHARMACEUTICAL COMPANY DONATES 400,000 TABLETS TO LOUISIANA FOR CLINICAL TRIALS IN COVID-19 TREATMENT

WBRZ- | March 30, 2020

news image

Louisiana Attorney General Jeff Landry, working with the assistance of State Senate Health and Welfare Chairman Fred Mills issued a statement Monday, announcing that Amneal Pharmaceuticals is donating 400,000 hydroxychloroquine sulfate tablets to the State of Louisiana to assist with the COVID-19 pandemic. "On behalf of Louisiana, I want to thank Amneal for this generous donation," said General Landry. "Amneal's donation is one step toward trying to find treatments and cures f...

Read More
news image

PHARMACY MARKET

IQVIA AND NRX PHARMACEUTICALS COLLABORATE ON POTENTIAL MEDICAL SUPPORT FOR NOVEL COVID-19 TREATMENT

IQVIA™ | September 14, 2021

IQVIA™ , a leading global provider of advanced analytics, technology solutions and clinical research services to the life sciences industry, today announced a transformative collaboration with NRx Pharmaceuticals (NRx). NRx is a company dedicated to creating innovative, life-saving treatments and bringing hope to those facing life-altering conditions with no approved disease-modifying therapies or cures. IQVIA is excited to collaborate with NRx as its designated partner, to provide pharmac...

Read More
news image

BUSINESS INSIGHTS

ANOKION ANNOUNCES $35 MILLION EQUITY INVESTMENT FROM PFIZER

Anokion | October 19, 2022

Anokion SA, a clinical-stage biotechnology company focused on treating autoimmune disease by restoring normal immune tolerance announced that Pfizer has made a $35 million equity investment in Anokion through the Pfizer Breakthrough Growth Initiative. In conjunction with the investment, Michael Vincent, M.D., Ph.D., senior vice president and chief scientific officer, Inflammation & Immunology, Pfizer, has joined the company’s scientific advisory board, which will be announced later thi...

Read More
news image

MAJOR PHARMA COMPANIES INCLUDING NOVARTIS AND MERCK BUILD FEDERATED LEARNING PLATFORM FOR DRUG DISCOVERY

Venturebeat | September 17, 2020

Last June, 10 major pharmaceutical companies — Amgen, Astellas, AstraZeneca, Bayer, Boehringer Ingelheim, GSK, Institut De Recherches Servier, Janssen, Merck, and Novartis — inked an agreement to build a shared platform called MELLODDY (Machine Learning Ledger Orchestration for Drug Discovery). In partnership with Nvidia, Owkin, and other tech partners, the group sought to leverage techniques like federated learning to collectively train AI on datasets without having to share any pro...

Read More
news image

NEW JERSEY PHARMACEUTICAL COMPANY DONATES 400,000 TABLETS TO LOUISIANA FOR CLINICAL TRIALS IN COVID-19 TREATMENT

WBRZ- | March 30, 2020

Louisiana Attorney General Jeff Landry, working with the assistance of State Senate Health and Welfare Chairman Fred Mills issued a statement Monday, announcing that Amneal Pharmaceuticals is donating 400,000 hydroxychloroquine sulfate tablets to the State of Louisiana to assist with the COVID-19 pandemic. "On behalf of Louisiana, I want to thank Amneal for this generous donation," said General Landry. "Amneal's donation is one step toward trying to find treatments and cures f...

Read More